Oncology Early Phase / Multiple Disease Site Hematologic Malignancies Early Phase Team Leukemia AML Relapsed/Refractory 1 or more prior lines
Categories
Protocols
BEIGENE-BGB-11417-103 Phase I/II OPEN TO ACCRUAL
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients with Myeloid Malignancies